The invention relates to a compound of the formula (I) Ar(NHSO.sub.2Ar.sup.1)1(SO.sub.2NHAr.sup.1).sub.m(NHC(O)NHAr.sup.2).sub.n (I), wherein 1 and m independently of one another are 0, 1, 2, 3, and/or 4 and the sum of is equal to or more than 1, n is 2, 3, 4, or 5, Ar is a benzol group which is substituted (i+m+n) times, Ar.sup.1 is an unsubstituted or substituted aromatic group, and Ar.sup.2 is an unsubstituted or substituted phenyl group or a benzoyl group. The invention also relates to a heat-sensitive recording material comprising a carrier substrate and a heat-sensitive color-forming layer which contains at least one color former and at least said color developer.

The invention relates to a compound of the formula (I) Ar(NHSO.sub.2Ar.sup.1)1(SO.sub.2NHAr.sup.1).sub.m(NHC(O)NHAr.sup.2).sub.n (I), wherein 1 and m independently of one another are 0, 1, 2, 3, and/or 4 and the sum of is equal to or more than 1, n is 2, 3, 4, or 5, Ar is a benzol group which is substituted (i+m+n) times, Ar.sup.1 is an unsubstituted or substituted aromatic group, and Ar.sup.2 is an unsubstituted or substituted phenyl group or a benzoyl group. The invention also relates to a heat-sensitive recording material comprising a carrier substrate and a heat-sensitive color-forming layer which contains at least one color former and at least said color developer.

Benzenesulfonyl-asymmetric ureas are provided for the treatment of conditions modulated by the ghrelin receptor.

Benzenesulfonyl-asymmetric ureas are provided for the treatment of conditions modulated by the ghrelin receptor.

The present invention discloses a biaryl urea RORt inhibitor, and specifically relates to a biaryl urea derivative, as represented by formula I, with an RORt inhibiting activity, and a preparation process thereof, and a pharmaceutical composition comprising the compound. Further disclosed is use of the compound for treating an RORt-related disease.

##STR00001##

The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation. ##STR00001##

The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation. ##STR00001##

The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.

##STR00001##

The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.

##STR00001##

The invention contemplates novel materials as anticonvulsant agents.